Tri-functional Imaging Agent for Monoclonal Antibody Tumor-Targeted Imaging
Posted Aug 04 2013 8:00pm
Description of Invention: This is a novel lysine-based trifunctional chelate which bears both a chelating moiety (CHX-A") for sequestering radiometals (86Y or 111In) and a near-infrared dye, e.g., Cy5.5, for dual modality PET (or SPECT) and fluorescence imaging. Successful conjugation of monoclonal antibody trastuzumab (Herceptin) or cetuximab (Erbitux), has also been achieved by efficient thiol-maleimide chemistry, thereby yielding an immunoconjugate (Signaling agent (Cy5.5-Lys(SMCC)-CHX-A") conjugated to trastuzumab) or (Signaling agent (Cy7-Lys(SMCC)-CHX-A") conjugated to cetuximab). Both specifically target antigen expressing cells and internalization of the agent has been imaged over time. Trastuzumab can be radiolabeled with isothiocyanate derivatives of the bifunctional chelating agents 1B4M (2-(4-aminobenzy1)-6-methyldiethylenetriaminepentaacetic acid); and CHX-A" (N-[(R)-2-amino-3-(p-aminophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-N,N,N',N",N"-pentaacetic acid).
Multifunctional (imageable through multiple platforms)
Collaborative Research Opportunity: The National Cancer Institute Radiation Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, Trifunctional Imaging Agent for Monoclonal Antibody Tumor-Targeted Imaging. For collaboration opportunities, please contact John D. Hewes, Ph.D. at firstname.lastname@example.org for more information.
For Licensing Information Please Contact: Michael Shmilovich Esq. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5019 Fax: 301-402-0220